**4. Therapeutic perspective of membrane receptors for inflammatory diseases**

The inflammatory process (edema, cell migration, pain, and other) treatment mainly uses non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids.


#### **Table 6.**

*Receptor antagonist compounds highlighted in clinical trials for inflammatory diseases.*

NSAIDs inhibit eicosanoid metabolites produced for the COX pathway, whereas corticosteroids are based on hormones released by the endocrine glands [132]. On the other hand, the more serious problem with these drugs is their prolonged use in treatments, presenting toxicity to organs. Based on this, the membrane receptors discussed in this chapter are promisor candidates for inflammation treatment. In addition, some classes possess agonists and antagonists commercially available among these receptors, such as 5-HT receptors and HRs.

Interestingly, clinical trials have already been realized and described in the literature concerning other membrane receptor types for reducing inflammatory diseases and their symptoms (**Table 6**). Therefore, we highlight four receptors discussed in this chapter with great potential in modulating the inflammation (TLR4, HR4, P2X7R, and TRPV1).
